Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

105

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
15/26/15	€0.1500	-6.25%	93,000
13/26/13	€0.1600	0.00%	2,000
10/26/10	€0.1600	0.00%	0
09/26/09	€0.1600	0.00%	20,000
08/26/08	€0.1600	0.00%	38,000

Delayed Quote Börse Stuttgart

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1803USD

Average target price

1.000USD

Spread / Average Target

+454.63%

Consensus

Annual profits - Rate of surprise

Company calendar

Market Closed - Börse Stuttgart Other stock markets 01:26:12 15/07/2026 am IST			5-day change	1st Jan Change
0.1500 ^EUR	-6.25%		-11.76%	-27.18%

09/07	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
16/05	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	30Cr 26Cr 24Cr 22Cr 42Cr 2.87TCr 43Cr 288.08Cr 113.03Cr 1.41TCr 112.32Cr 109.84Cr 4.84TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	40Cr 35Cr 32Cr 29Cr 56Cr 3.8TCr 57Cr 380.64Cr 149.34Cr 1.86TCr 148.41Cr 145.13Cr 6.4TCr	EV / Sales 2026 *	-	EV / Sales 2027 *	10.9x
Free-Float	95.04%	Yield 2026 *	-	Yield 2027 *	-

09/07	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
16/05	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
21/04	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
16/04	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
15/11	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/11	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
31/25/31	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
27/25/27	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
24/25/24	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
27/25/27	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI
18/25/18	Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman	CI
15/25/15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

08/07	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
02/07	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
16/05	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
30/04	Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform	PR
21/04	Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic	PR

Northwest Biotherapeutics, Inc. Share Price Börse Stuttgart

Stocks

NBYB

US66737P6007

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc.

Chart: Northwest Biotherapeutics, Inc.

Latest news : Northwest Biotherapeutics, Inc.

Press Releases: Northwest Biotherapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Northwest Biotherapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

1 day	-6.25%
1 week	-11.76%
Current month	+3.45%
1 month	-16.67%
3 months	-6.25%
6 months	-28.57%
Current year	-27.18%

1 week	0.12	0.18
1 month	0.1	0.21
Current year	0.1	0.38
1 year	0.1	0.38
3 years	0.1	1.02
5 years	0.1	2.18
10 years	0.1	2.18

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	01/06/2007
Linda Powers CEO	Chief Executive Officer	71	08/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	01/01/2000

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	01/01/1998
Linda Powers CHM	Chairman	71	17/05/2007
Navid Malik BRD	Director/Board Member	57	01/04/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHWEST BIOTHERAPEUTICS, INC.	-6.25%	-11.76%	-	-	30Cr
WUXI APPTEC CO., LTD.	+6.05%	+3.69%	+65.28%	+89.94%	5.35TCr
ARGENX SE	+0.21%	-6.37%	+58.42%	+128.79%	5.42TCr
INSMED INCORPORATED	+0.89%	-2.42%	+8.07%	+434.51%	2.37TCr
BIONTECH SE	+0.37%	-4.13%	-18.56%	-16.48%	2.28TCr
WUXI BIOLOGICS (CAYMAN) INC.	+2.36%	+1.06%	+43.34%	-6.14%	1.95TCr
GENMAB A/S	-2.29%	+1.78%	+34.98%	-28.10%	1.78TCr
PHARMAESSENTIA CORPORATION	-4.00%	-7.88%	+175.60%	+343.60%	1.6TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.15%	-4.83%	+46.53%	+627.30%	1.54TCr
EXELIXIS, INC.	-0.48%	-2.30%	+22.36%	+187.62%	1.41TCr
Average	-0.40%	-1.47%	+48.44%	+195.67%	2.63TCr
Weighted average by Cap.	+1.20%	-0.46%	+49.54%	+163.99%

	2026 *	2027 *
Net sales	-	3.89Cr 3.4Cr 3.15Cr 2.91Cr 5.47Cr 373.98Cr 5.57Cr 38Cr 15Cr 183.12Cr 15Cr 14Cr 630.54Cr
Net income	-	-
Net Debt	9.61Cr 8.4Cr 7.76Cr 7.17Cr 14Cr 922.87Cr 14Cr 93Cr 36Cr 451.9Cr 36Cr 35Cr 1.56TCr	12Cr 11Cr 10Cr 9.32Cr 18Cr 1.2TCr 18Cr 120.37Cr 47Cr 587.63Cr 47Cr 46Cr 2.02TCr